Payment overview · 2025
General Payments
$862.62
16 reported records · 8 companies
Healthcare provider profile · identity verified
Li Kong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1942680897
Verified facts
What the public records show
CMS Open Payments records show Li Kong, M.D. received $862.62 in general payments during 2025 across 16 reported records.
Phathom Pharmaceuticals, Inc. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $279.87 | 32.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 14.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.33 | 14.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.19 | 12.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.36 | 10.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.27 | 10.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.80 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.80 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $862.62 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $279.87 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.33 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $109.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.27 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 56 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
56 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 104 |
| Losartan Potassium | Losartan Potassium | 324 | 109 |
| Vascepa | Icosapent Ethyl | 324 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 96 |
| Metformin Hcl | Metformin Hcl | 208 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 54 |
| Alendronate Sodium | Alendronate Sodium | 162 | 55 |
| Donepezil Hcl | Donepezil Hcl | 132 | 50 |
| Jardiance | Empagliflozin | 128 | 40 |
| Omeprazole | Omeprazole | 123 | 52 |
| Diclofenac Epolamine | Diclofenac Epolamine | 122 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 38 |
| Trazodone Hcl | Trazodone Hcl | 93 | 46 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 85 | 28 |
| Januvia | Sitagliptin Phosphate | 81 | 19 |
| Simvastatin | Simvastatin | 69 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 22 |
| Finasteride | Finasteride | 67 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 42 |
| Farxiga | Dapagliflozin Propanediol | 63 | 18 |
| Metformin Hcl Er | Metformin Hcl | 60 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 34 |
| Icosapent Ethyl | Icosapent Ethyl | 58 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 44 |
| Creon | Lipase/Protease/Amylase | 56 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 18 |
| Azithromycin | Azithromycin | 45 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Acarbose | Acarbose | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 27 |
| Cyclosporine | Cyclosporine | 35 | 16 |
| Eliquis | Apixaban | 35 | 13 |
| Hydrocortisone | Hydrocortisone | 35 | 16 |
| Ibuprofen | Ibuprofen | 35 | 26 |
| Linzess | Linaclotide | 35 | 13 |
| Ammonium Lactate | Ammonium Lactate | 34 | 16 |
| Atenolol | Atenolol | 34 | 11 |
| Clotrimazole | Clotrimazole | 34 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Famotidine | Famotidine | 29 | 11 |
| Ketoconazole | Ketoconazole | 29 | 12 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | 13 |
| Ciclopirox | Ciclopirox | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | 16 |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Tacrolimus | Tacrolimus | 25 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Restasis | Cyclosporine | 24 | 13 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | 15 |
| Mesalamine | Mesalamine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Prolia | Denosumab | 14 | 11 |
| Allopurinol | Allopurinol | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $862.62 · 16 records | Phathom Pharmaceuticals, Inc. | CREON, ESPRIT, FARXIGA, KISUNLA, Kerendia, LINZESS, OTEZLA, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error